Dechert LLP
Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors
Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.
Genzyme Corporation
C C A A A A A C A A A A A A A
C07D C07D A61K A61K A61P A61P A61K C07B A61K A61P A61K A61P A61P A61P A61K
inventional inventional inventional inventional inventional inventional inventional additional additional inventional inventional inventional inventional inventional inventional
Donglai Michael Harvey Chris C. Michael
Yang Santos Lieberman Ho Philbrook